Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Melanoma 2Carcinosarcoma 2Bile Duct Neoplasms 2Advanced Solid Tumours 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour Refractory to Conventional Treatment 1Salivary Gland Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × ceralasertib × Clear all
NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04239014 2021-03-10

DUETTE

AstraZeneca

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡